Please login to the form below

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life science companies can cut through the noise to drive uptake of innovative therapies, including novel TYK2 inhibitors.

During the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell targeted therapies and tumor necrosis factor (TNF) inhibitors have given patients therapeutic options beyond traditional treatments such as topical steroids, tar preparations, oral systemics, and light therapy. Suddenly, those with more severe psoriasis had safer and more effective treatment options that delivered the life-changing potential for clear skin.

Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors, and the latest ‘game changer’ Tyrosine kinase 2 (TYK2) inhibitors.

The healthcare press has described TYK2 inhibitors as having the potential to revolutionize psoriasis treatment. The inhibitors work by blocking the action of TYK2 and preventing the downstream signaling effects of cytokines IL-12, IL-23, and type I interferons, thereby clinically improving psoriatic plaques.

In contrast to many existing treatments for more difficult-to-control forms of psoriasis which are intravenous, TYK2 inhibitors– like Bristol Myers Squibb’s deucravacitinib (BMS-986165) –are being trialed as oral medications, which could vastly improve the patient experience. The results of the deucravacitinib Phase 3 studies caused a stir across the industry. A significant number of patients achieved a Psoriasis Area and Severity Index (PASI) 75 response, which means the patients' score on the index dropped by 75%, and a static Physician’s Global Assessment Score of clear or almost clear (sPGA 0/1).

In a disease where the impact on patients’ quality of life has been likened to other chronic illnesses, like diabetes and coronary heart disease, the impact of these novel treatments could be ground-breaking. However, despite the increasing number of treatments available, a survey by the U.S National Psoriasis Foundation found 52% of patients with psoriasis are dissatisfied with treatment. In addition, recent data show moderate and severe psoriasis are often undertreated with more than 50% of patients prescribed only topical therapies.

So, if striving for clear or almost clear skin is a realistic treatment goal, why are healthcare professionals refraining from prescribing more efficacious treatments, and what does this mean for yet-to-be approved TYK2 inhibitors?

Download the full article to: 

  • Explore the treatment landscape
  • Learn about the barriers keeping healthcare professionals from prescribing treatments beyond topicals
  • Find out about strategies for driving uptake of novel psoriasis therapies.

Download the PDF here

16th July 2021

Share

Tags

Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

Address:
No. 3 Booths Park
Booths Hall
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom

Latest content on this profile

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life science companies can cut through the noise to drive uptake of innovative therapies, including novel TYK2 inhibitors.
Fishawack Health
Healthcare tech: the driving force behind value-based care?
In 2020, healthcare technology investment went into overdrive. We speak to Sunny Kumar, Partner at GSR Ventures, to find out how COVID‑19 has transformed the industry and whether healthcare technology can bring us one step closer to a value-based model of care.
Fishawack Health
Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can be an essential tool for medical affairs, bringing data to life and engaging patients and healthcare professionals in novel and more meaningful ways.
Fishawack Health
Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience.
Fishawack Health
Welcoming analytics-driven digital marketing agency closerlook to the Fishawack Health pack
Fishawack Health enhances its omnichannel capabilities with the acquisition of closerlook, a data analytics and digital native healthcare agency specializing in intelligent omnichannel marketing solutions.
Fishawack Health
The rise of the healthcare social media influencer
The consumer industry has long been leveraging the power of social media influencers with enormous success. But can the highly regulated healthcare industry achieve the same results? Daniel Brackins explores the influencer marketing opportunities for life science companies and answers your questions.
Fishawack Health